Gene Therapy 2 for Oncology is under clinical development by Alaunos Therapeutics and currently in Phase I for Lymphoma. According to GlobalData, Phase I drugs for Lymphoma have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Gene Therapy 2 for Oncology’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gene Therapy 2 for Oncology overview
Gene therapy is under development for the treatment of lymphoma, leukemia. The therapeutic candidate is composed of T cells expressing CD19-specific chimeric antigen receptors (CAR) and a membrane-bound interleukin 15 (IL15). The development of the drug candidate is based on RheoSwitch technology.
It was also under development for the treatment relapsed or refractory acute lymphoblastic leukemia, follicular lymphoma, mantle cell lymphoma relapsed lymphoblastic leukemia and diffuse large B-cell lymphoma.
Alaunos Therapeutics overview
Alaunos Therapeutics formerly ZIOPHARM Oncology, is a biopharmaceutical company which provides next-generation immune therapies. The company carries out the development and commercialization of in-licensed cancer drugs. It offers controlled IL-12 which provides therapy for cold tumors by turning them hot by activating an immune response and t-cell therapy to fight blood cancers and solid tumors. Alaunos Therapeutics also offers Sleeping Beauty Technology, a clinically advanced non-viral cell therapy technology which helps in the manufacturing of genetically modified chimeric antigen receptors (CARs) and T-cell receptors (TCRs) targeting specific tumor-derived antigens. Its products and technologies are used in the treatment of hematologic malignancies, solid tumors and graft-versus-host-disease. Alaunos Therapeutics is headquartered in Boston, Massachusetts, the US.
For a complete picture of Gene Therapy 2 for Oncology’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
